News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA) is predicted by Wall Street analysts to post quarterly earnings of $0.08 per share, reflecting a decline of 87.9% compared to the same period last year. Revenues are forecasted to be $4.1 billion, representing a …
Sharemaestro market context Trend signal active 52 weeks +82.5% · Next-week setup negative 42.4%Rubric Capital Management LP reduced its stake in Teva Pharmaceutical Industries (TEVA) by 28.6% in the first quarter, though it remains their fourth-largest holding with a value of approximately $459.3 million. Despite this reduction, other institutional investors increased their positions, pushing overall institutional ownership …
Cetera Investment Advisers increased its stake in Corteva, Inc. (NYSE:CTVA) by 7.7% in the first quarter, now holding 228,580 shares valued at $19.13 million. Other institutional investors also acquired new positions in the company. Analysts have issued new price targets for Corteva, with a …
Teva Pharmaceutical Industries is shifting its focus from generics to higher-margin branded drugs, with a significant bet on duvakitug for ulcerative colitis and Crohn's disease, which could be a multi-billion-dollar opportunity. This pivot, alongside other branded neurology and psychiatry initiatives, aims to reshape investor …
Corteva has announced a Q3 2026 distribution of R$ 0.15 per unit for holders of its BDRs (ISIN BRC1TVBDR007). Shares will trade with entitlement through August 28, and payment is scheduled for September 21. This news brief was generated by Public Technologies (PUBT) using …
This article details the shareholder structure of Stevanato Group SpA (STVN), listing major institutional holders and their respective proportions. Key shareholders include Conestoga Capital Advisors, LLC, Neuberger Berman, LLC, and T. Rowe Price Investment Management, Inc. The report also provides a breakdown of shareholder …
This article provides a detailed company profile for Corteva Inc (CTVA), a global pure-play agriculture company specializing in seed and crop protection solutions. It includes financial data, market performance metrics like market cap and P/E ratio, and details on its business segments, key executives, …
Sei Investments Co. increased its stake in Teva Pharmaceutical Industries Ltd. by 22.5% in the first quarter, bringing its total holding to $35.62 million. While institutional investors collectively own 54.05% of Teva and analysts maintain a "Moderate Buy" rating, company insiders have sold approximately …
First Trust Advisors LP significantly reduced its stake in Corteva, Inc. ($CTVA) by 43.8% in the first quarter, selling over 465,000 shares. Despite this, other institutional investors like Brighton Jones LLC and Woodline Partners LP increased their holdings. Wall Street analysts maintain a positive …
This article details the shareholder structure of Corteva Inc (CTVA), listing its major institutional holders, types of shareholders, and recent institutional shareholding trends. Key shareholders include Vanguard Capital Management, BlackRock, and State Street Investment Management, while investment advisors constitute the largest shareholder type. The …
Bank of Nova Scotia trimmed its stake in Corteva, Inc. (NYSE:CTVA) by 52.3% in the first quarter, selling 120,104 shares and reducing its holdings to 109,660 shares valued at $9.18 million. Meanwhile, other institutional investors have increased their positions in Corteva, and analysts maintain …
Analysts are projecting a 60% upside and maintain a 100% buy rating for Teva Pharmaceutical Industries (TEVA), citing potential blockbuster drugs in its pipeline. However, the stock's technical chart shows bearish pressure, with the price trading below key moving averages and momentum indicators confirming …
Stevanato Group (STVN) reported its Q1 2023 earnings, missing both EPS and revenue estimates. The company posted an actual EPS of $0.13 against a consensus of $0.14, and revenue of $255.35M compared to an expected $267.16M, though still achieving a YoY revenue growth of …
Key Points Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead. With high potential to become a blockbuster drug, duvakitug could help …
Key Points Teva's business is shifting away from generic drugs toward branded drugs. Operating margins could soar through next year, boosting earnings potential. The stock has plenty of upside, justifying Wall Street's optimistic price targets.10 stocks we like better than Teva Pharmaceutical Industries › …
Lombard Odier Asset Management Europe Ltd reduced its stake in Corteva, Inc. by 11.9% during the first quarter, holding shares valued at $13.90 million. Several other institutional investors also adjusted their positions in Corteva during the same period. The article also details recent analyst …
Teva Pharmaceutical Industries Limited (TEV) has released its Q4 2025 earnings report, significantly beating analyst expectations. The company reported actual EPS of €0.84 against a consensus of €0.56 and actual revenue of €4.18 billion, surpassing the expected €3.79 billion. Teva's revenue also showed a …
Teva Pharmaceutical Industries Limited (BX:TEV) generated 13.68 billion CHF in revenue last year, primarily from its Generics, Innovative Medicines and Biopharmaceuticals segment. This is a decrease from 15.03 billion CHF in the previous year. The United States was the largest contributor to revenue, accounting …
This article provides a detailed breakdown of Corteva Inc.'s (CTVA) revenue by business segments and geographical regions. As of April 6 (updated), Corn contributes the largest share to its business revenue, followed by Herbicides, while North America accounts for over half of its regional …
Corteva, Inc. (NYSE:CTVA) announced a quarterly dividend of $0.18 per share, payable on September 15th to shareholders of record on September 1st. The company has consistently raised its dividend for the past five years, supported by a low payout ratio of 20.5%. Analysts anticipate …
Corteva, Inc. (CTVA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant …
Sharemaestro market context Trend signal ended 52 weeks +5.5% · Next-week setup positive 55.7%Corteva, Inc. CTVA is likely to witness growth in its top and bottom lines when it reports second-quarter fiscal 2026 results on July 30, after the opening bell. The Zacks Consensus Estimate for quarterly revenues is pegged at $6.61 billion, indicating a 2.4% dip …
Sharemaestro market context Trend signal active 52 weeks +1.2%Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Dividend affirmation and earnings expectations set the tone Corteva (CTVA) has reaffirmed a common stock dividend of $0.18 per share, payable on September …
Sharemaestro market context Trend signal ended 52 weeks +5.5% · Next-week setup positive 55.7%Corteva, Inc. announced its quarterly dividend will remain at $0.18 per share. The dividend is payable on September 15, 2026, to shareholders of record as of September 1, 2026. This information was officially released by MT Newswires.
Corteva Inc. (NYSE:CTVA) announced a quarterly common stock dividend of $0.18 per share, payable on September 15, 2026, to shareholders of record as of September 1, 2026. Additionally, the Board of Directors of EIDP Inc., a Corteva subsidiary, declared preferred stock dividends of $1.125 …
Corteva, Inc. (NYSE: CTVA) announced a common stock dividend of $0.18 per share, payable on September 15, 2026, to shareholders of record as of September 1, 2026. Separately, EIDP, a wholly-owned subsidiary of Corteva, declared regular preferred dividends on its $4.50 and $3.50 series, …
INDIANAPOLIS, July 24, 2026 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) today announced its Board of Directors has authorized a common stock dividend of $0.18 cents per share, payable September 15, 2026, to the Company's shareholders of record on September 1, 2026. EIDP, Inc. Announces …
Sharemaestro market context Trend signal active 52 weeks +1.2%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Corteva stock has more than doubled over the past five years, yet its valuation signals are pulling in different directions, with a Discounted Cash Flow (DCF) intrinsic …
Sharemaestro market context Trend signal active 52 weeks +1.2%Stevanato Group SpA (STVN) is experiencing healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. The stock is rated as a "Buy" by multiple analysts, with a target price of 25.175, indicating a significant …
Sei Investments Co. increased its stake in Corteva, Inc. (NYSE:CTVA) by 2.9% in the first quarter, now owning 1,572,931 shares valued at approximately $131.67 million. Other institutional investors also adjusted their positions in the agricultural company, which reported strong quarterly earnings and announced a …
Corteva, Inc. recently drew increased analyst attention as expectations rose that its June 2026 quarter would exceed prior earnings forecasts on higher revenues. Analysts are highlighting Corteva's history of topping consensus earnings estimates and a positive Earnings ESP, which together are fueling confidence ahead …
Sharemaestro market context Trend signal ended 52 weeks +5.5% · Next-week setup positive 55.7%President Donald Trump’s threat of 100% tariffs on generic drugs would seem to be a problem for Teva Pharmaceutical. It might not be. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +71.0%Oppenheimer has maintained an Outperform rating for Corteva (CTVA) and raised its price target to $95.00 from $89.00, reflecting confidence in the company's growth potential. Despite this positive analyst sentiment, GuruFocus indicates that CTVA is currently overvalued with a GF Value™ of $64.80 compared …
Oppenheimer raised Corteva's (NYSE:CTVA) price target to $95.00 from $89.00, maintaining an "outperform" rating and suggesting a 7.6% upside. This follows strong Q1 results where Corteva beat EPS and revenue estimates. Several other firms have also increased their price targets, leading to a consensus …
Oppenheimer has increased its price target for Corteva (CTVA) to $95 from $89, reiterating an Outperform rating on the stock. This adjustment reflects analyst confidence in the agricultural chemicals company. Other recent analyst actions also show upward revisions to Corteva's price targets.
Search by ticker symbol or company name and select a result to open its chart.